Steris PLC (NYSE:STE) – Analysts at Northcoast Research upped their FY2018 earnings estimates for shares of Steris in a report issued on Thursday. Northcoast Research analyst D. Keiser now expects that the medical equipment provider will post earnings per share of $4.13 for the year, up from their previous forecast of $4.08. Northcoast Research has a “Buy” rating and a $102.00 price objective on the stock. Northcoast Research also issued estimates for Steris’ Q4 2018 earnings at $1.22 EPS, Q1 2019 earnings at $0.99 EPS, Q2 2019 earnings at $1.12 EPS, Q4 2019 earnings at $1.39 EPS and FY2019 earnings at $4.77 EPS.
A number of other equities analysts also recently commented on STE. KeyCorp restated an “overweight” rating and set a $101.00 target price (up previously from $91.00) on shares of Steris in a report on Thursday, November 2nd. Zacks Investment Research lowered shares of Steris from a “buy” rating to a “sell” rating in a research note on Monday, November 6th. TD Securities upped their target price on shares of Steris from C$14.00 to C$16.00 and gave the company a “buy” rating in a research note on Thursday, November 9th. Finally, Raymond James Financial upped their target price on shares of Steris from $95.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, October 16th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Steris presently has an average rating of “Buy” and an average target price of $84.80.
Steris (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 EPS for the quarter, topping the consensus estimate of $1.07 by $0.05. Steris had a net margin of 9.42% and a return on equity of 11.57%. The company had revenue of $661.90 million during the quarter, compared to the consensus estimate of $663.17 million. During the same quarter last year, the firm posted $0.98 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in STE. Citigroup Inc. acquired a new position in Steris in the 2nd quarter valued at $206,000. Parametric Portfolio Associates LLC raised its stake in shares of Steris by 6.2% during the second quarter. Parametric Portfolio Associates LLC now owns 24,973 shares of the medical equipment provider’s stock worth $2,035,000 after buying an additional 1,460 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Steris by 4.3% during the second quarter. Dimensional Fund Advisors LP now owns 576,920 shares of the medical equipment provider’s stock worth $47,021,000 after buying an additional 23,793 shares during the last quarter. Stifel Financial Corp raised its stake in shares of Steris by 14.5% during the second quarter. Stifel Financial Corp now owns 10,808 shares of the medical equipment provider’s stock worth $881,000 after buying an additional 1,370 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Steris by 53.2% during the second quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock worth $190,392,000 after buying an additional 811,622 shares during the last quarter. Hedge funds and other institutional investors own 89.63% of the company’s stock.
In related news, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Sudhir K. Pahwa sold 2,000 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $92.09, for a total transaction of $184,180.00. The disclosure for this sale can be found here. Corporate insiders own 2.55% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/09/fy2018-eps-estimates-for-steris-plc-ste-increased-by-analyst.html.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.